Jacob L. Kool
Centers for Disease Control and Prevention
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Jacob L. Kool.
Emerging Infectious Diseases | 2002
Jeroen W. Den Boer; Ed P. F. Yzerman; Joop Schellekens; Kamilla D. Lettinga; H.C. Boshuizen; Jim E. van Steenbergen; A Bosman; Susan van den Hof; Hans van Vliet; Marcel F. Peeters; Ruud J. van Ketel; Peter Speelman; Jacob L. Kool; Marina A.E. Conyn-van Spaendonck
In 1999, an outbreak of Legionnaires’ disease affected many visitors to a flower show in the Netherlands. To identify the source of the outbreak, we performed an environmental investigation, as well as a case-control study among visitors and a serologic cohort study among exhibitors to measure exposure to possible sources. Of 77,061 visitors, 188 became ill (133 confirmed and 55 probable cases), for an attack rate of 0.23% for visitors and 0.61% for exhibitors. Two whirlpool spas in halls 3 and 4 of the exhibition and a sprinkler in hall 8 were culture positive for Legionella pneumophila. One of three genotypes found in both whirlpool spas was identical to the isolates from 28 of 29 culture-positive patients. Persons who paused at the whirlpool spa in hall 3 were at increased risk for becoming ill. This study illustrates that whirlpool spas may be an important health hazard if disinfection fails.
Infection Control and Hospital Epidemiology | 2002
Marc-Alain Widdowson; Gerard J. J. van Doornum; Wim H. M. van der Poel; Annette S. de Boer; Reina van de Heide; Ulrike Mahdi; Paul Haanen; Jacob L. Kool; Marion Koopmans
OBJECTIVE In December 1999, an outbreak of diarrhea was reported in a general hospital neonatal medium care unit (NMCU) caused by a novel strain of rotavirus with genotype P[6], G9. An investigation was conducted to determine risk factors for illness among neonates. DESIGN Rotavirus diagnosis was by latex agglutination and typing by reverse transcriptase polymerase chain reaction. A case-control study was performed using data collected from medical records on exposures in a 3-day period before illness (cases) or a random 3-day period (controls). Environmental swabs were tested for rotavirus. Antenatal blood samples from mothers and blood samples provided by hospital staff were analyzed for rotavirus antibodies. RESULTS Fifty-six cases of rotaviral illness were confirmed by latex agglutination. Forty-seven of these were among 118 neonates exposed to the NMCU (attack rate, 40%). There was a 4-week period with no clinical cases in the course of the outbreak. Increased frequency (> or = 15 times in 3 days) of ungloved nasogastric feeding was a significant risk factor (adjusted odds ratio, 8.79), controlling for birth weight and gestational age. Environmental sampling showed persistence of the virus on ward surfaces despite cleaning. None of 24 NMCU staff members had high levels of antibodies against P[6], G9. Three (8%) of 38 mothers had high antibody levels; 2 had infants who became ill. The outbreak ended with a 7-day ward closure, disinfection, and introduction of gloved nasogastric feeding. CONCLUSIONS Case-control studies can be successful in identiffying risk factors for nosocomial outbreaks of diarrhea. High levels of rotavirus antibodies in mothers may not protect infants. The environment may be the most important reservoir of rotavirus during outbreaks.
Emerging Infectious Diseases | 2004
Jeannine M. Petersen; Martin E. Schriefer; Leon G. Carter; Yan Zhou; Tara K. Sealy; Darcy A. Bawiec; Brook Yockey; Sandra K. Urich; Nordin S. Zeidner; Swati B. Avashia; Jacob L. Kool; Jan Buck; Connie Lindley; Leos Celeda; John A. Monteneiri; Kenneth L. Gage; May C. Chu
Oropharyngeal tularemia was identified as the cause of a die-off in captured wild prairie dogs at a commercial exotic animal facility in Texas. From this point source, Francisella tularensis–infected prairie dogs were traced to animals distributed to the Czech Republic and to a Texas pet shop. F. tularensis culture isolates were recovered tissue specimens from 63 prairie dogs, including one each from the secondary distribution sites. Molecular and biochemical subtyping indicated that all isolates were F. tularensis subsp. holarctica (Type B). Microagglutination assays detected antibodies against F. tularensis, with titers as great as 1:4,096 in some live animals. All seropositive animals remained culture positive, suggesting that prairie dogs may act as chronic carriers of F. tularensis. These findings demonstrate the need for additional studies of tularemia in prairie dogs, given the seriousness of the resulting disease, the fact that prairie dogs are sold commercially as pets, and the risk for pet-to-human transmission.
Emerging Infectious Diseases | 2006
Elizabeth M. Begier; Gershim Asiki; Zaccheus Anywaine; Brook Yockey; Martin E. Schriefer; Philliam Aleti; Asaph Ogen-Odoi; J. Erin Staples; Christopher Sexton; Scott W. Bearden; Jacob L. Kool
In a case cluster, pneumonic plague transmission was compatible with respiratory droplet rather than aerosol transmission.
Emerging Infectious Diseases | 2004
Swati B. Avashia; Jeannine M. Petersen; Connie Lindley; Martin E. Schriefer; Kenneth L. Gage; Marty Cetron; Thomas A. DeMarcus; David K. Kim; Jan Buck; John A. Montenieri; Jennifer L. Lowell; Michael F. Antolin; Michael Y. Kosoy; Leon G. Carter; May C. Chu; Katherine A. Hendricks; David T. Dennis; Jacob L. Kool
A tularemia outbreak, caused by Francisella tularensis type B, occurred among wild-caught, commercially traded prairie dogs. F. tularensis microagglutination titers in one exposed person indicated recent infection. These findings represent the first evidence for prairie-dog-to-human tularemia transmission and demonstrate potential human health risks of the exotic pet trade.
Emerging Infectious Diseases | 2003
Timothy H. Holtz; Joel Ackelsberg; Jacob L. Kool; Richard Rosselli; Anthony A. Marfin; Thomas Matte; Sara T. Beatrice; Michael B. Heller; Dan Hewett; Linda C. Moskin; Michel L. Bunning; Marcelle Layton
On October 31, 2001, in New York City, a 61-year-old female hospital employee who had acquired inhalational anthrax died after a 6-day illness. To determine sources of exposure and identify additional persons at risk, the New York City Department of Health, Centers for Disease Control and Prevention, and law enforcement authorities conducted an extensive investigation, which included interviewing contacts, examining personal effects, summarizing patient’s use of mass transit, conducting active case finding and surveillance near her residence and at her workplace, and collecting samples from co-workers and the environment. We cultured all specimens for Bacillus anthracis. We found no additional cases of cutaneous or inhalational anthrax. The route of exposure remains unknown. All environmental samples were negative for B. anthracis. This first case of inhalational anthrax during the 2001 outbreak with no apparent direct link to contaminated mail emphasizes the need for close coordination between public health and law enforcement agencies during bioterrorism-related investigations.
Infection Control and Hospital Epidemiology | 2000
Udo Buchholz; Chesley L. Richards; Rekha Murthy; Matthew J. Arduino; Doreen Pon; Wayne Schwartz; Elsie Fontanilla; Clare F. Pegues; Noemy Boghossian; Carol L. Peterson; Jacob L. Kool; Laurene Mascola; William R. Jarvis
OBJECTIVE To identify risk factors associated with an unexpected outbreak of pyrogenic reactions (PR) following intravenous gentamicin. DESIGN We conducted two cohort studies. PRs were defined as chills, rigors, or shaking within 3 hours after initiating the gentamicin infusion during the preepidemic (December 1, 1997-January 15, 1998) or epidemic (May 1-June 15, 1998) periods. We tested gentamicin vials for endotoxin using the limulus amebocyte lysate assay. SETTING Inpatient services of a large community hospital in Los Angeles, California. RESULTS During the epidemic period, 22 (15%) of 152 patients developed documented PRs following intravenous gentamicin. PRs were more likely among patients receiving single daily dosing (SDD) than multiple daily dosing gentamicin (20/73 [27%] vs. 2/79 [3%]; relative risk, 10.8; 95% confidence interval, 2.6 44.7). Laboratory analysis of gentamicin vials found endotoxin levels that were higher among Fujisawa-brand gentamicin (implicated brand) than gentamicin used after the outbreak terminated (non-implicated brand). Although endotoxin levels in the vials did not exceed US Pharmacopeia limits (1.7 endotoxin units/mg gentamicin), the use of SDD gentamicin may place patients at greater risk of receiving doses of endotoxin above the threshold for PRs in humans. CONCLUSIONS Reassessment of the acceptable amounts of endotoxin in gentamicin and other parenteral products should be considered when dosing intervals used in clinical practice change.
Infection Control and Hospital Epidemiology | 1999
Jacob L. Kool; David Bergmire-Sweat; Jay C. Butler; Ellen W. Brown; Deborah J. Peabody; Daniel S. Massi; Joseph Carpenter; Janet M. Pruckler; Robert F. Benson; Barry S. Fields
Infection Control and Hospital Epidemiology | 1998
Jacob L. Kool; Anthony E. Fiore; Clare M. Kioski; Ellen W. Brown; Robert F. Benson; Janet M. Pruckler; Constance Glasby; Jay C. Butler; Gary D. Cage; Joseph Carpenter; Richard M. Mandel; Bob England; Robert F. Breiman
The Lancet | 1999
Jacob L. Kool; Joseph Carpenter; Barry S. Fields